Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 747,888 | 662,972 | 528,216 | 503,528 | 597,395 |
| Receivables | 24,649 | 21,910 | 21,606 | 46,124 | 49,166 |
| Other current assets | 28,566 | 29,223 | 37,338 | 32,023 | 38,107 |
| TOTAL | $812,845 | $714,105 | $587,160 | $584,145 | $714,269 |
| Non-Current Assets | |||||
| PPE Net | 103,931 | 111,706 | 120,038 | 126,834 | 141,063 |
| Intangibles | 472,061 | 484,386 | 505,589 | 493,902 | 484,728 |
| Other Non-Current Assets | 85,293 | 89,329 | 89,568 | 100,353 | 108,538 |
| TOTAL | $661,285 | $685,421 | $715,195 | $721,089 | $734,329 |
| Total Assets | $1,474,130 | $1,399,526 | $1,302,355 | $1,305,234 | $1,448,598 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 18,118 | 13,935 | 19,314 | 25,086 | 21,613 |
| Accrued Expenses | 70,230 | 73,360 | 84,538 | 56,804 | 81,872 |
| Other current liabilities | 37,605 | 47,364 | 39,690 | 39,651 | 61,767 |
| TOTAL | $147,707 | $155,103 | $164,026 | $141,981 | $187,472 |
| Non-Current Liabilities | |||||
| Long Term Debt | 9,564 | 11,902 | 14,196 | 16,446 | 19,022 |
| Other Non-Current Liabilities | 162,739 | 162,261 | 181,203 | 190,423 | 190,747 |
| TOTAL | $195,558 | $197,475 | $219,183 | $229,306 | $226,344 |
| Total Liabilities | $343,265 | $352,578 | $383,209 | $371,287 | $413,816 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 527,398 | 520,643 | 434,152 | 406,495 | 401,991 |
| Common Shares | 5 | 5 | 4 | 4 | 4 |
| Retained earnings | -2,076,002 | -1,967,879 | -1,805,589 | -1,633,694 | -1,431,283 |
| Other shareholders' equity | 36,717 | 34,093 | 43,620 | 14,145 | -7,637 |
| TOTAL | $1,130,865 | $1,046,948 | $919,146 | $933,947 | $1,034,782 |
| Total Liabilities And Equity | $1,474,130 | $1,399,526 | $1,302,355 | $1,305,234 | $1,448,598 |